Clinical Trial

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of \[18F\]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2026-02-19; most recent amendment 2026-06-22.
Trial Details
NCT Number NCT07432633
Lead Sponsor Blue Earth Diagnostics
Collaborators: Medpace, Inc.
Conditions Colorectal Cancer, Epithelial Ovarian Cancer, Gastric Cancer, Invasive Lobular Breast Carcinoma, Pancreatic Ductal Adenocarcinoma
Enrollment 71 participants
Start Date 2026-02-19
Primary Completion 2028-01-31 (estimated)
Study Completion 2028-01-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-23